Yuhan Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (22)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Yuhan - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Yuhan. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Yuhan - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Yuhan - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Yuhan. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Yuhan - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Yuhan

  1.1 Business Overview

  1.2 Yuhan Cancer Pipeline Overview

 

2. Yuhan Cancer Drugs in Preclinical Phase

  2.1 Anti-Cancer Therapeutics - Sorrento Therapeutics

  2.2 Protein Kinase Inhibitors – Genosco

  2.3 AC 103

  2.4 AC 101

  2.5 AC 104

  2.6 Immune Checkpoint Antibodies - ImmuneOncia Therapeutics

  2.7 Small Interfering RNA Therapeutics – Yuhan

  2.8 YH 24931

  2.9 YH NCE4

  2.10 YH 25448

  2.11 KRS Inhibitors - Yuhan Corporation

 

3. No Development Reported in Cancer Drugs in Clinical Pipeline

  3.1 Oncolytic Virus - Yuhan Corporation

  3.2 Incrementally Modified Cancer Therapeutic - Yuhan Corporation

 

4. Discontinued in Cancer Drugs in Clinical Pipeline

  4.1 Anti-Cancer Gene Therapy - Yuhan Corporation

  4.2 Anti-Cancer Immunomodulators - Yuhan Corporation


Figure 1-1: Yahan Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1 2: Yahan Cancer Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)